Purdue Didn't Slip Through the Cracks. The Government Helped Build the Door.

On December 12, 1995, a federal agency signed off on a drug.¹ Not in 1996, the year everyone remembers—the year of the launch, the year of the marketing.² The signature came earlier, and it mattered, because the label the FDA approved told doctors that OxyContin's slow-release formula reduced the drug's "abuse liability"—language written into the approved label and carried into every sales call that followed.¹² That sentence was not smuggled in. It was reviewed, edited, and stamped by the government. The fraud did not slip past the watchdog. The watchdog held the pen.

The story we tell about Purdue Pharma is a story about a single rogue family that got rich poisoning a country and was finally caught. The neater version goes: they sold $35 billion of pills,⁶ they were fined, they went bankrupt, justice arrived. Almost every beat of that story is true and the sequence is a lie—because at each step, the thing that was supposed to stop Purdue instead handed it the next exit.

The fine that punished a shell

Look closely at the 2007 'reckoning,' the one cited everywhere as the moment Purdue was held to account. On May 10, 2007, a guilty plea to felony misbranding was entered, and $600 million was paid—roughly ninety percent of OxyContin's profits during the offense period, the Senate record notes.⁴ But read the caption on the case. The defendant was The Purdue Frederick Company, an affiliate, not Purdue Pharma L.P. itself.³ The felony belonged to an entity. The three executives who actually ran the marketing—Friedman, Udell, Goldenheim—pleaded only to misdemeanor misbranding and paid $34.5 million between them.³ Nobody named Sackler was charged. The corporation took the conviction; the people walked out under it. The machine paid the toll for the men who operated it.

Here is the part the 2007 story is built to make you forget. The crime did not stop. In 2020, Purdue Pharma L.P.—the real company this time, not an affiliate—entered a second federal guilty plea, to three felonies: conspiring to defraud the DEA and violating the Anti-Kickback Statute. The conduct it admitted ran from May 2007 through at least March 2017.⁵ Read those dates against the calendar. The decade of new felonies began the same month as the settlement everyone calls the end of it. The reckoning was a checkpoint the company drove straight through.

How bankruptcy almost bought the owners their freedom

By the time Purdue filed for Chapter 11 in September 2019, the Sackler family had pulled roughly $11 billion out of the company in distributions—about $4.6 billion of it earmarked for taxes, according to the Supreme Court's own recital of the record.⁶ Earlier figures circulating before the bankruptcy record was fully developed put the family's total withdrawals lower. And the family that took the money did not file for bankruptcy. The company did.⁹ That asymmetry was the whole design. A debtor in bankruptcy gets its slate wiped in exchange for surrendering its assets to creditors. The Sacklers proposed to buy the same protection—release from civil opioid claims—without ever putting themselves in bankruptcy at all. They would contribute a sum to the pot, and in return, a Chapter 11 plan would extinguish everyone's right to sue them personally, whether the claimants agreed or not.

That maneuver had a name in the bankruptcy bar—the nonconsensual third-party release—and for years it had worked. Lower courts had blessed the roughly $6 billion 2022 plan precisely because the alternative looked worse: tie the deal up, and victims might get nothing for another decade. The genius of the structure was that it turned the family's money into a shield, and dared anyone to knock it away knowing the cost would fall on the dying. It was not a loophole the Sacklers found. It was an architecture the legal system had been building for everyone with enough money to use it.

It took the Supreme Court, in June 2024, to be the first branch of government that actually shut the exit. By a single vote, the Court held that Chapter 11 cannot discharge claims against people who never entered bankruptcy themselves, not without the consent of those giving up their right to sue.⁷ The ~$6 billion plan collapsed. And then something instructive happened: a new deal emerged, $7.4 billion—$1.4 billion more than before—confirmed by the bankruptcy court in November 2025.⁸ Closing the cheap exit raised the price of the real one. The immunity, it turned out, had been undervalued.

Isn't this just one greedy family, full stop?

The fair objection is that this lets the Sacklers off the hook by blaming the referee. Purdue chose to mislead doctors; the family chose to take the money; no FDA reviewer or bankruptcy judge forced their hands, and the moral weight sits squarely on them. All true—and it misses the point of asking why the crime ran for almost thirty years. A rogue actor that the system catches early is a contained problem. What makes Purdue a structural story, not just a moral one, is that the institutions designed to stop it were the same ones that, at every stage, supplied the next move: a label the regulator approved, a plea that convicted an entity instead of the people, a bankruptcy doctrine that converted cash into immunity. You do not need to absolve the family to notice that they kept finding the door already open. The honest read is that personal culpability and institutional complicity are not competing explanations. They are the same machine, viewed from two ends.

Purdue Pharma sold more than $35 billion of OxyContin and routed $11 billion of it into a family that, for three decades, was never the one in the dock.⁶ The drug got the regulator's blessing, the affiliate took the felony, the executives took the misdemeanor, and the bankruptcy almost took the lawsuits off the table for good. Each stop on that road is remembered as a moment justice arrived. Each was really a moment the system handed Purdue the next key. The fall, when it finally came, was not the market punishing a bad company or a watchdog catching a bad family. It was one court, by a single vote, refusing to keep a door open that everyone else had spent thirty years holding.